Compare LFMD & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFMD | ESPR |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United States |
| Employees | 384 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.9M | 793.7M |
| IPO Year | N/A | 2013 |
| Metric | LFMD | ESPR |
|---|---|---|
| Price | $3.89 | $2.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $9.14 | $7.60 |
| AVG Volume (30 Days) | 1.2M | ★ 4.6M |
| Earning Date | 03-09-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $403,135,000.00 |
| Revenue This Year | $17.76 | $0.69 |
| Revenue Next Year | $17.66 | $10.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $2.60 | $0.73 |
| 52 Week High | $15.34 | $4.18 |
| Indicator | LFMD | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 39.98 |
| Support Level | $3.43 | $2.37 |
| Resistance Level | $4.20 | $3.02 |
| Average True Range (ATR) | 0.35 | 0.19 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 54.49 | 37.04 |
LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.